[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.248.103. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

June 2020 - April 2015

Decade

Year

Issue

June 2020, Vol 6, No. 6, Pages 801-942

Original Investigation

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study

Abstract Full Text
open access has active quiz
JAMA Oncol. 2020;6(6):831-838. doi:10.1001/jamaoncol.2020.0910

This phase 2 randomized clinical trial evaluates the outcomes of combined immune checkpoint inhibition plus best supportive care vs best supportive care alone for patients with advanced colorectal cancer.

Association of Utilization Management Policy With Uptake of Hypofractionated Radiotherapy Among Patients With Early-Stage Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(6):839-846. doi:10.1001/jamaoncol.2020.0449

This economic analysis assesses the association of a large commercial payer’s utilization management policy with use of hypofractionated radiotherapy and associated spending among women with early-stage breast cancer.

Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer: A Nonrandomized Controlled Trial

Abstract Full Text
JAMA Oncol. 2020;6(6):848-855. doi:10.1001/jamaoncol.2019.6731

This phase 1 nonrandomized controlled trial assesses the safety and tolerability of programmed cell death 1 inhibition concurrently with definitive chemoradiotherapy compared with programmed cell death 1 inhibition and radiotherapy in patients with non–small cell lung cancer.

Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(6):856-864. doi:10.1001/jamaoncol.2020.0409

This phase 2 randomized clinical trial evaluates the safety and efficacy of the combination treatment of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non–small cell lung cancer.

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

Abstract Full Text
has audio
JAMA Oncol. 2020;6(6):865-871. doi:10.1001/jamaoncol.2020.0726

This cohort study examines case reports from a large, international pharmacovigilance database to determine the recurrence rate of adverse events associated with continuing immunotherapy drugs for patients with cancer.

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial

Abstract Full Text
JAMA Oncol. 2020;6(6):872-880. doi:10.1001/jamaoncol.2020.0750

This phase 2 randomized clinical trial assesses the efficacy of concomitant and sequential treatment with nivolumab and doxorubicin, vinblastine, and dacarbazine (AVD) for patients with early-stage unfavorable Hodgkin lymphoma.

Factors Associated With Chemoradiation Therapy Interruption and Noncompletion Among Patients With Squamous Cell Anal Carcinoma

Abstract Full Text
JAMA Oncol. 2020;6(6):881-887. doi:10.1001/jamaoncol.2020.0809

This cohort study examines rates of chemoradiation treatment interruption or noncompletion and identifies factors associated with this among patients with anal cancer treated in routine clinical practice.

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

Abstract Full Text
JAMA Oncol. 2020;6(6):888-894. doi:10.1001/jamaoncol.2020.0930

This multicenter phase 2 study evaluates the anticancer activity of nivolumab in patients with advanced refractory biliary tract cancer.

Association Between Breastfeeding and Ovarian Cancer Risk

Abstract Full Text
online only
JAMA Oncol. 2020;6(6):e200421. doi:10.1001/jamaoncol.2020.0421

This pooled analysis analyzes the association between breastfeeding (ie, ever/never, duration, timing) and ovarian cancer risk overall and by histotype.

Brief Report

Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial

Abstract Full Text
JAMA Oncol. 2020;6(6):895-899. doi:10.1001/jamaoncol.2020.1052

This double-blinded, randomized, placebo-controlled clinical trial evaluates the utility of olanzapine for treating chronic nausea/vomiting in patients with advanced cancer.

Research Letter

Positron Emission Tomography Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(6):921-923. doi:10.1001/jamaoncol.2020.0334

This nonrandomized clinical trial tested [18F]FluorThanatrace as a method for measuring regional poly–(adenosine diphosphate–ribose) polymerase 1 expression in breast cancer and as a potential functional biomarker for breast cancer poly–(adenosine diphosphate–ribose) polymerase inhibitor response.

e-Cigarette Use Among Young Adult Cancer Survivors Relative to the US Population

Abstract Full Text
JAMA Oncol. 2020;6(6):923-926. doi:10.1001/jamaoncol.2020.0384

This survey study uses data from the 2018 Behavioral Risk Factor Surveillance System survey to evaluate e-cigarette use in young adults who have a history of cancer relative to young adults without cancer.

The Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology Meetings

Abstract Full Text
JAMA Oncol. 2020;6(6):926-927. doi:10.1001/jamaoncol.2020.0475

This quality improvement analysis of oral presentations of phase 3 randomized clinical trials evaluates the frequency and risks of emphasizing results of borderline significance.

Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib

Abstract Full Text
JAMA Oncol. 2020;6(6):927-929. doi:10.1001/jamaoncol.2020.0571

This secondary analysis of data from the HERACLES-A clinical trial examines long-term outcomes in 32 patients with colorectal cancer treated with trastuzumab and lapatinib.

Staying at One’s Job to Maintain Employer-Based Health Insurance Among Cancer Survivors and Their Spouses/Partners

Abstract Full Text
JAMA Oncol. 2020;6(6):929-932. doi:10.1001/jamaoncol.2020.0742

This study examines the prevalence at which cancer survivors and their spouses/partners in the US stay at their jobs to maintain employer-based health insurance.

Review

Evidence Underlying Policy Proposals for Sustainable Anticancer Drug Prices: A Systematic Review

Abstract Full Text
JAMA Oncol. 2020;6(6):909-916. doi:10.1001/jamaoncol.2019.6846

This systematic review evaluates an inventory of policies to reduce drug prices at market launch and analyzes the quantitative evidence on which these policies are based.

JAMA Oncology Clinical Challenge

Cardiac Masses in a Patient With Pancreatic Adenocarcinoma and a History of Breast Carcinoma

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(6):917-918. doi:10.1001/jamaoncol.2020.0086

A 64-year-old woman with borderline resectable pancreatic adenocarcinoma and a history of hormone receptor–positive left-sided breast cancer had several hypodense lesions in the apex of her heart on chest computed tomography and several discrete, partially mobile frondlike masses originating from her cardiac apex on transthoracic echocardiography. What is your diagnosis?

Viewpoint

The Ethics of Delivering Precision Medicine—Pretest Counseling and Somatic Genomic Testing

Abstract Full Text
JAMA Oncol. 2020;6(6):815-816. doi:10.1001/jamaoncol.2020.0016

This Viewpoint advocates for clinicians, health care systems, and professional organizations to adopt standards on the use of somatic testing, including pretest and posttest genetic counseling and education.

Better Understanding the Importance of Palliative Care for Pediatric Patients

Abstract Full Text
JAMA Oncol. 2020;6(6):817-818. doi:10.1001/jamaoncol.2020.0083

This Viewpoint discusses issues involved in implementing palliative care programs for pediatric patients.

Supervision Requirements in the 2020 Hospital Outpatient Prospective Payment System: Implications for Cancer Care in the United States

Abstract Full Text
JAMA Oncol. 2020;6(6):819-820. doi:10.1001/jamaoncol.2020.0092

This Viewpoint discusses the Centers for Medicare and Medicaid Services new rule for the Hospital Outpatient Prospective Payment System and the possible implications for patient safety and quality of care for patients with cancer.

Editorial

Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer—Fact or Fiction?

Abstract Full Text
JAMA Oncol. 2020;6(6):823-824. doi:10.1001/jamaoncol.2020.0504
Invited Commentary

Evaluating a Utilization Management Policy in Radiation Oncology

Abstract Full Text
JAMA Oncol. 2020;6(6):846-847. doi:10.1001/jamaoncol.2020.0447
Cancer Care Chronicles

Caring for Patients With Cancer During the COVID-19 Outbreak in Italy

Abstract Full Text
free access has active quiz
JAMA Oncol. 2020;6(6):821-822. doi:10.1001/jamaoncol.2020.1426

This essay discusses the challenges associated with caring for patients with cancer during the COVID-19 epidemic in Italy.

Poetry and Oncology

Bone Marrow Biopsy

Abstract Full Text
JAMA Oncol. 2020;6(6):942. doi:10.1001/jamaoncol.2020.0388
Comment & Response

Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer

Abstract Full Text
JAMA Oncol. 2020;6(6):932. doi:10.1001/jamaoncol.2020.0283

Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(6):932-933. doi:10.1001/jamaoncol.2020.0289

Determining the Appropriate Risk-Adapted Screening Age for Familial Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(6):933-934. doi:10.1001/jamaoncol.2020.0286

Determining the Appropriate Risk-Adapted Screening Age for Familial Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(6):934-935. doi:10.1001/jamaoncol.2020.0292

Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma

Abstract Full Text
JAMA Oncol. 2020;6(6):935. doi:10.1001/jamaoncol.2020.0340

Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma—Reply

Abstract Full Text
JAMA Oncol. 2020;6(6):935-936. doi:10.1001/jamaoncol.2020.0343

Defining the Right State for a Will Rogers Phenomenon in Oligometastatic Prostate Cancer

Abstract Full Text
JAMA Oncol. 2020;6(6):936-937. doi:10.1001/jamaoncol.2020.0574

The Role of Maintenance Therapy in Metastatic Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2020;6(6):937. doi:10.1001/jamaoncol.2020.0580

The Role of Maintenance Therapy in Metastatic Colorectal Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(6):937-938. doi:10.1001/jamaoncol.2020.0583

Association of Acupuncture and Acupressure With Improved Cancer Pain

Abstract Full Text
JAMA Oncol. 2020;6(6):938. doi:10.1001/jamaoncol.2020.0616

Association of Acupuncture and Acupressure With Improved Cancer Pain

Abstract Full Text
JAMA Oncol. 2020;6(6):938-939. doi:10.1001/jamaoncol.2020.0619

Association of Acupuncture and Acupressure With Improved Cancer Pain

Abstract Full Text
JAMA Oncol. 2020;6(6):939-940. doi:10.1001/jamaoncol.2020.0622

Association of Acupuncture and Acupressure With Improved Cancer Pain—Reply

Abstract Full Text
JAMA Oncol. 2020;6(6):940. doi:10.1001/jamaoncol.2020.0640

Obesity Paradox in Patients With Non–Small Cell Lung Cancer Treated With Immunotherapy

Abstract Full Text
JAMA Oncol. 2020;6(6):940-941. doi:10.1001/jamaoncol.2020.0634

Obesity Paradox in Patients With Non–Small Cell Lung Cancer Treated With Immunotherapy—Reply

Abstract Full Text
JAMA Oncol. 2020;6(6):941-942. doi:10.1001/jamaoncol.2020.0643
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2020;6(6):801. doi:10.1001/jamaoncol.2019.4227
×